Treatment of fatigue in patients with stable coronary heart disease by sulbuthiaminum

Introduction . Asthenia is an exhausting symptom accompanying coronary heart disease (CHD). Aim . Assess the effectiveness of asthenic syndrome therapy with sulbutiamin in patients with CHD. Materials and methods . Asthenia was diagnosed in 2.373 outpatients with chronic non-communicable diseases. Of the 282 participants with stable CHD, asthenia was diagnosed in 131 (mean age 65.3 ± 10.5 years, 74 women and 57 men). Asthenia was indicated using MFI-20 and FSS scales. Patients were divided into three groups: Group 1 – 63 patients without Sulbutiaminum and lifestyle change, Group 2 – 38 patients who changed their lifestyle, Group 3 – 30 patients who changed their lifestyle and received sulbutiamine 600 mg/day for 4 weeks. Results . The first screening showed the median total score on the FSS scale in the 3rd group was 43.5 points and was significantly higher than in the 1st and 2nd groups (41.0 and 42.0 points). On the MFI-20 scale, the median total score in the 3rd group was 59.5 points and significantly exceeded the indicators of the 2nd group (50.5 points). In dynamics, the 3rd group showed a significant decrease on the MFI-20 scale to 34.0 and a decrease on the FSS scale to normal 28.0 points (р = 0.001). Analysis of the asthenia subtypes in the 3rd group revealed a significant decrease in the indicators of decreased activity to 6.0 points and of mental asthenia to 4.0 points (р = 0.001). Conclusion . The results show high efficiency of lifestyle modification and Sulbutiaminum treatment in patients with CHD and asthenia.